Kymera Therapeutics
KT-474 is an IRAK4 degrader (co-developed with Sanofi) whose structural basis for selective and potent IRAK4 degradation was published in Nature Communications, underpinning dermatology and autoimmunity indications.
- Country
- United States
- Ticker
- KYMR
IRAK4 degrader (KT-474)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| PROTACs (targeted protein degradation) | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.